Central Composite Design-Optimized Dabigatran Etexilate Cubosomes for Sustained Oral Release and Enhanced In Vivo Pharmacokinetics.
OBJECTIVES Dabigatran etexilate mesylate (DEM), a prodrug of the direct thrombin inhibitor dabigatran used for stroke prevention in nonvalvular atrial fibrillation, exhibits poor aqueous solubility, P-glycoprotein-mediated efflux, and limited oral bioavailability, which pose challenges for oral delivery. This study aim...